Sosa v. Sweet

CourtDistrict Court, D. Connecticut
DecidedMarch 30, 2023
Docket3:20-cv-00382
StatusUnknown

This text of Sosa v. Sweet (Sosa v. Sweet) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sosa v. Sweet, (D. Conn. 2023).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT ANDRES SOSA, ) 3:20-CV-382 (SVN) Plaintiff, ) ) v. ) ) CHRISTOPHER SWEET, et al., ) Defendants. ) March 30, 2023 ) ) RULING AND ORDER ON DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT Sarala V. Nagala, United States District Judge. In this civil rights action, Plaintiff Andres Sosa, a sentenced inmate in the custody of the Connecticut Department of Correction (“DOC”), alleges that Defendants—Dr. Craig Burns, Dr. Robert Berger, and Advanced Practice Registered Nurses (“APRN”) Andrea Reischerl and Carole Wright—were all involved in, or otherwise supported, the decision to stop treating Plaintiff with a mental health medication called Wellbutrin. Plaintiff alleges that this decision showed deliberate indifference to Plaintiff’s mental health and well-being, in violation of the Eighth Amendment to the United States Constitution. Presently before the Court is Defendants’ motion for summary judgment, seeking to dismiss the complaint in its entirety. For the reasons described below, the Court GRANTS Defendants’ motion. I. FACTUAL BACKGROUND1 A. Plaintiff’s Medical History Plaintiff, who was housed at Corrigan-Radgowski Correctional Center during the relevant time period, has a fairly lengthy mental health treatment history; the Court includes only the information necessary for the instant motion. In May of 2015, Plaintiff was diagnosed with, among

other things, depression, impulse disorder, and suicidal threats. Def’s L.R. 56(a)1 St., ECF No. 121 ¶ 10. A few months later, in October and November 2015, Plaintiff was prescribed Wellbutrin and Zoloft, respectively, to treat these mental health issues. Id. ¶ 8.2 As Plaintiff’s claims largely center around his access to Wellbutrin, the Court briefly addresses the nature and uses of this drug. Wellbutrin currently has an “FDA indication” as a treatment for major depressive disorder and seasonal affective disorder, and to assist a patient in efforts to quit smoking. Id. ¶ 18. An “FDA indication” means that there is sufficient data for the United States Food and Drug Administration to certify that a given medication is safe and effective as a treatment for a specific ailment. Id. ¶ 19. That Wellbutrin does not have an indication for any other psychiatric disorder

indicates, at a minimum, there is insufficient data to support the effectiveness of Wellbutrin at treating those other disorders. Id. ¶ 20.

1 Initially, many of the facts in the instant litigation are disputed by the parties. In fact, in Plaintiff’s Local Rule 56(a)2 Statement he has disputed, or objected to, nearly every fact presented by Defendants in their Local Rule 56(a)1 Statement. See ECF No. 134 at 19–41. Many of these objections, however, are made only on the ground that “Plaintiff lacks personal knowledge to the defendant’s [sic] allegations here and leave it up [sic] to their proof.” See, e.g., Pl.’s L.R. 56(a)2 St. ¶¶ 18–25, 28–31, 33–39, 41, 49, 51–61, 64–65, 68, 74, 76–78. Such objections simply point the Court to the proof offered by Defendants for each of these paragraphs but do not present any evidence or argument as to why such facts are disputed. Thus, where Plaintiff has made only an objection of this type, and Defendants’ assertion is supported by evidence in the record, the Court will deem the fact admitted for purposes of summary judgment. See D. Conn. L. R. 56(a)3. Where a fact is undisputed, or deemed admitted, the Court cites only to Defendants’ Local Rule 56(a)1 Statement. 2 Plaintiff objects to this assertion, insofar as he asserts that he was actually taking several additional medications. Pl.’s L.R. 56(a)2 St., ECF No. 134 ¶ 8. While this may be true, for purposes of the present motion it is only relevant that Plaintiff was on Wellbutrin. In addition to its approved uses, Wellbutrin can also be crushed and inhaled through the nose to provide a high similar to cocaine. Id. ¶ 25. For that reason, if an inmate has a prescription for Wellbutrin but chooses not to use it themselves, there is a market within prisons for that inmate to potentially resell the medication. Id. If Wellbutrin is ultimately passed to someone who does not have a prescription for it, and that individual ingests the drug, it could have severe

consequences, including possible death. Id. To prevent this, individuals receiving mental health medications, including Wellbutrin, are directly observed by medical staff while the pills are administered. Id. This is done to ensure the inmates are correctly taking the medication as prescribed. Id. At some point after Plaintiff was prescribed Wellbutrin, though precisely when is not clear from the parties’ submissions, Defendants began to suspect that Plaintiff was “cheeking” or “palming” his medications. Id. ¶ 9. Both of these behaviors are strategies that allow a patient not to take his or her medication when it is distributed, but, rather, to keep it for later use. Id. 3 In addition, and apparently unrelated to, the palming and cheeking, on August 24, 2016,

Plaintiff had his first appointment with Defendant Wright, who is an APRN and is board-certified as a family nurse practitioner and a psychiatric mental health nurse practitioner. Id. ¶¶ 12, 66. She was the primary prescriber assigned to Corrigan-Radgowski Correctional Center, and had authority and autonomy in the treatment of inmates housed in the facility. Id. ¶ 64. During this appointment, Defendant Wright began to question whether Plaintiff’s medication was effective. Id. This was because Plaintiff reported that he felt helplessness, stress, and that his anger was out

3 Plaintiff objects to Defendants’ evidence in support of their contention that Plaintiff was not taking his medication correctly on the ground that the records offered are inadmissible hearsay and should not be considered on a motion for summary judgment. Pl.’s L.R. 56(a)(2) St. ¶ 9. Defendants have not filed a reply addressing this contention. While the Court believes Plaintiff may well be correct in his argument, it need not, and will not, resolve this hearsay objection because Defendants’ allegations regarding Plaintiff cheeking and palming his Wellbutrin are not necessary to the Court’s resolution of Defendants’ motion. of control. Id. After hearing this update from Plaintiff, Defendant Wright specifically began to question whether the Wellbutrin, as a stimulant, was increasing his irritability and anger. Id. When Defendant Wright attempted to discuss whether to remove Plaintiff from Wellbutrin, however, Plaintiff became agitated and demanded he be put on another medication called Ativan instead. Id. In response, Defendant Wright promised to review Plaintiff’s treatment plan and medication

prior to their next appointment. Id. Plaintiff next had an appointment with Defendant Wright on October 26, 2016. Id. ¶ 13. During this appointment, Plaintiff informed Defendant Wright that his current level of medication was not working for him, and he requested an increased dosage. Id. Defendant Wright discussed Plaintiff’s present and past medication history and the efficacy of each. Id. After this discussion, Defendant Wright began to question whether Plaintiff actually suffered from antisocial personality disorder, rather than the previously-diagnosed depression. Id. Importantly, antisocial personality disorder is a condition not treated with medication, but, rather, is addressed through “programming and learning life skills.” Id. ¶ 17. Based on these doubts, and that antisocial personality disorder

is not treated with Wellbutrin, Defendant Wright determined that she would discontinue prescribing Wellbutrin to Plaintiff. Id. ¶ 13. Almost a month later, on December 21, 2016, Plaintiff returned to see Defendant Wright. Id. ¶ 14. During this appointment Plaintiff requested he be placed back on Wellbutrin. Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gregg v. Georgia
428 U.S. 153 (Supreme Court, 1976)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Erickson v. Pardus
551 U.S. 89 (Supreme Court, 2007)
Ventura v. Sinha
379 F. App'x 1 (Second Circuit, 2010)
Tracy v. Freshwater
623 F.3d 90 (Second Circuit, 2010)
Brown v. Eli Lilly and Co.
654 F.3d 347 (Second Circuit, 2011)
Colon v. Coughlin
58 F.3d 865 (Second Circuit, 1995)
Chance v. Armstrong
143 F.3d 698 (Second Circuit, 1998)
Walker v. Schult
717 F.3d 119 (Second Circuit, 2013)
Farmer v. Brennan
511 U.S. 825 (Supreme Court, 1994)
Tangreti v. Bachmann
983 F.3d 609 (Second Circuit, 2020)
Kee v. City of New York
12 F.4th 150 (Second Circuit, 2021)
Blyden v. Mancusi
186 F.3d 252 (Second Circuit, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
Sosa v. Sweet, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sosa-v-sweet-ctd-2023.